Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Bristol-Myers Squibb reports positive phase III data for Opdivo in advanced melanoma patients Bristol-Myers Squibb Company has announced positive results from CheckMate -037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab).
Drug Research > Drug Discovery & Development > News
Kamada announces second extension of strategic agreement with Baxter Kamada, a plasma-derived protein therapeutics company focused on orphan indications, announced today the second extension to supply Glassia to Baxter in its strategic agreement with the biopharmaceutical business of Baxter International.
Drug Research > Drug Discovery & Development > News Takeda to invest $25m in drug discovery firm BioMotiv By PBR Staff Writer
Japanese drug maker Takeda Pharmaceutical is planning to invest $25m in BioMotiv, a drug discovery company associated with The Harrington Project for Discovery & Development.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Circulomics gets Phase I SBIR to develop nanobind extraction method for FFPE samples
Circulomics has been awarded a Phase I Small Business Innovative Research (SBIR) grant by the National Institutes of Health (NIH) to develop its Nanobind DNA and RNA isolation technology for formalin-fixed, paraffin-embedded (FFPE) samples.
Drug Research > Drug Discovery & Development > News
Polipharma Industries - Pharmaceutical Product Manufacturer
Polipharma Industries is a GMP-certified drug manufacturer established in 2003, whose core business is the manufacturing of pharmaceutical products. We provide activities and services such as: research & development, out-licensing, contract manufacturing, contract development, batch release, analytical services and clinical trials.
Drug Research > Drug Discovery & Development > Suppliers
FibroGen reports one-year data of FG-3019 in patients with Idiopathic Pulmonary Fibrosis
FibroGen has announced the presentation of the full data set from a clinical study of patients with idiopathic pulmonary fibrosis (IPF) treated for 48 weeks with the investigational drug FG-3019.
Drug Research > Drug Discovery & Development > News
Novo Nordisk's Phase IIIb trial of Ryzodeg fails to meet primary endpoint
By PBR Staff Writer
Novo Nordisk has reported results from a 26-week randomized multinational Phase IIIb trial, which showed that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen.
Drug Research > Drug Discovery & Development > News
Boehringer, CureVac to develop next generation lung cancer immunotherapy
By PBR Staff Writer
Boehringer Ingelheim has entered into an exclusive global license and development agreement with CureVac to develop the latter's new investigational therapeutic mRNA vaccine CV9202 to treat lung cancer.
Drug Research > Drug Discovery & Development > News
Lupin and Merck Serono enter into strategic alliance
By PBR Staff Writer
Lupin and Merck Serono have entered into a strategic partnership to support the latter to broaden its general medicines portfolio in emerging markets.
Drug Research > Drug Discovery & Development > News
Cardiorentis announces €45m financing with HealthCare Royalty Partners
By PBR Staff Writer
Cardiorentis AG, a privately held biopharmaceutical company, announced that it has entered into a €45m financing agreement with HealthCare Royalty Partners (HC Royalty), a US based healthcare investment firm.
Drug Research > Drug Discovery & Development > News
Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study
By PBR Staff Writer
Glenmark Pharmaceuticals announced that its first in class Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown positive data in a Phase 2a double blind, placebo controlled, multi-centre, proof of concept study conducted on 138 patients in Europe and India.
Drug Research > Drug Discovery & Development > News
Boehringer, Eli Lilly present results from Phase III study of empagliflozin/linagliptin combination tablet for type 2 diabetes
By PBR Staff Writer
Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with type 2 diabetes (T2D) already taking metformin and in those who were previously untreated.
Drug Research > Drug Discovery & Development > News
Alnylam adds HDP treatment ALN-AGT to strengthen pipeline
By PBR Staff Writer
US-based biopharmaceutical firm Alnylam Pharmaceuticals has strengthened its pipeline with the addition of ALN-AGT, a subcutaneously administered RNAi therapeutic targeting angiotensinogen (AGT) indicated to treat hypertensive disorders of pregnancy (HDP), including preeclampsia.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250